Compare Recursion Pharmaceuticals Inc (RXRX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.81B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 99.4× Recursion Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SCHW | |
|---|---|---|
Market Cap | $1.86B | $184.81B |
Sector | Health | Financials |
52-Week High | $6.79 | $113.65 |
52-Week Low | $2.84 | $85.35 |
Enterprise Value | $1.38B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Charles Schwab (SCHW) trades at $106.87, down 2.21% today, as technical indicators signal bearish momentum with price near key support at $106. Fundamentally, the company shows strength with Q2 2026 EPS beating estimates at $1.62 versus $1.56 expected, and revenue growth accelerating to $23.92B in 2025. Analyst sentiment remains positive with 57% buy ratings and a $122.14 consensus target, representing 14% upside potential from current levels.
The outlook remains favorable given strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures from Vanguard's Altruist acquisition present risks. With robust cash flow generation and improving debt metrics, SCHW offers value for long-term investors despite current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
